US BROKER MOVES: CRWD upgraded at Morgan Stanley; NVO downgraded at TD Cowen

• Brunswick Corporation (BC) upgraded from Hold to Buy at Texas Capital Securities; PT $91.00
• Cellectar Biosciences (CLRB) upgraded from Hold to Buy at Maxim Group; PT $10.00
• CrowdStrike (CRWD) upgraded from Equalweight to Overweight at Morgan Stanley; PT $510.00 (prev. $487.00)
• Hims & Hers Health (HIMS) upgraded from Underperform to Neutral at BOFA Securities; PT $23.00 (prev. $12.50)
• Intuit (INTU) upgraded from Neutral to Buy at Rothschild Redburn; PT $700.00 (prev. $670.00)
• Rivian (RIVN) upgraded from Hold to Buy at TD Cowen; PT $20.00
• SolarEdge (SEDG) upgraded from Underperform to Neutral at BOFA Securities; PT $40.00 (prev. $17.00)
• AT&T (T) upgraded from Sell to Neutral at Arete; PT $28.00
• Teladoc Health (TDOC) upgraded from Hold to Buy at Deutsche Bank; PT $11.00
• Telus (TU) upgraded from Neutral to Buy at BOFA Securities; PT $22.00 (prev. $20.00)

• Novo Nordisk (NVO) downgraded from Buy to Hold at TD Cowen; PT $42.00 (prev. $45.00)
• PayPal (PYPL) downgraded from Buy to Neutral at Presidents Capital Management; PT $52.00
• Talkspace (TALK) downgraded from Outperform to Market Perform at Northland; PT $5.25 (prev. $7.00)
• Talkspace (TALK) downgraded from Overweight to Sector Weight at KeyBanc

• Amgen (AMGN) initiated at Hold at Jefferies; PT $350.00
• Strive (ASST) initiated at Buy at B.Riley; PT $12.00
• BridgeBio Pharma (BBIO) initiated at Outperform at William Blair
• BKV Corp (BKV) initiated at Buy at Citi; PT $36.00
• Crocs (CROX) initiated at Neutral at BTIG
• DY Comms (DY) initiated at Overweight at Cantor Fitzgerald
• Emcor (EME) initiated at Overweight at Cantor Fitzgerald; PT $848.00
• Gilead Sciences (GILD) initiated at Buy at Jefferies; PT $180.00
• Lowe’s (LOW) initiated at Neutral at KGI Securities; PT $255.00
• Maze Therapeutics (MAZE) initiated at Outperform at Mizuho; PT $97.00
• Strategy (MSTR) initiated at Buy at B.Riley; PT $175.00
• NeuroSense (NRSN) initiated at Buy at Roth/MKM; PT $3.00
• Qualcomm (QCOM) initiated at Underperform at BOFA Securities; PT $145.00
• Rocket Companies (RKT) initiated at Buy at Compass Point; PT $21.00
• UWM Holdings (UWMC) initiated at Buy at Compass Point; PT $8.50
• Vertex Pharmaceuticals (VRTX) initiated at Buy at Jefferies; PT $580.00
• WSFS Financial (WSFS) initiated at Buy at Brean Capital; PT $74.50

The recent upgrades and downgrades among several high-profile stocks indicate shifting sentiment in the market. For instance, CrowdStrike's upgrade to Overweight by Morgan Stanley suggests strong growth expectations and could lead to positive momentum in tech equities, while Novo Nordisk's downgrade highlights potential concerns within the healthcare sector that may weigh on its stock performance and influence broader market perceptions in pharmaceuticals.